semaj83/ctmatch_classification huggingface dataset:
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Adenomatous Polyposis Coli Patients with genetically or clinically proven Familial Adenomatous Polyposis. Genetically proven: Adenomatous Polyposis Coli (APC)-mutation identified. Clinically proven: more than 100 colorectal polyps at diagnosis Age 18 to 70 years Written informed consent Adequate potential for follow-up  Medical or psychiatric conditions that compromise the patient's ability to give informed consent Proctocolectomy MutYH mutation Concurrent uncontrolled medical conditions Pregnant or lactating women. Documentation of a negative pregnancy test must be available for woman of childbearing potential. Woman of childbearing potential are pre-menopausal women with intact reproductive organs and women less than two years after menopause
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Polyps Cases Patients who were diagnosed with or underwent resection of a duodenal adenoma/ampulloma at Westmead hospital between the years 2005-2014 Controls Patients undergoing VCE procedure for the evaluation of obscure gastrointestinal bleeding (OGIB) or Iron deficiency anemia (IDA)
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 40.0-70.0,  Colorectal Cancer Colorectal Adenoma First-degree relatives (aged 40 to 70 years) of individuals diagnosed with non-advanced adenoma on screening colonoscopy as Cases FDR of patients with negative findings on colonoscopy identified during the same study period, who are of the same age group as the studied as Cohort  A FDR history of CRC A family history compatible with that of Hereditary Non-polyposis Colon Cancer (HNPCC) based on the Amsterdam Known Familial Adenomatous Polyposis (FAP) syndrome Patients and siblings with known inflammatory bowel disease Undergone colonoscopy examinations in the past 5 years Severe cardio-pulmonary or other medical co-morbidities that preclude safe colonoscopic examination
Patient description: A 21-year-old college student undergoes colonoscopy due to family history of multiple polyps in his older siblings. His brother underwent total proctocolectomy at age 22, and his sister underwent a total proctocolectomy at age 28, after both were found to have hundreds of colonic adenomas on colonoscopy. Both siblings are currently well without any findings of neoplasms. The patient undergoes sigmoidoscopy and is found to have dozens of small colonic polyps within rectosigmoid. Several of these are biopsied and are all benign adenomas.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Adenomatous Polyp of Colon Adult patients (18-80 years) who are undergoing colonoscopy for screening or surveillance purposes  Patients with a prior history of colonic surgeries Patient with Crohns colitis or ulcerative colitis Patient with prior history of colon cancer Patient with poor bowel preparation Pregnant women
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 8.0-13.0,  Osteoporosis Pubertal stage II Calcium intake below a threshold level Caucasian Normal health  Medications affecting calcium and bone metabolism Chronic diseases Metabolic bone disease Abnormality in calcium metabolism
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Osteopenia Osteoporosis Women at least 60 years of age Good general health Willingness to participate in this 3.5 year study Ability to give informed consent Ability to live independently and travel to the research center for visits (we will provide transportation on a limited basis) Spine bone mineral density (BMD) (L1-4) T-score between -1.0 and -2.5, or a hip T-score between -1.0 and -2.5. A T-score of -1.0 is equal to a bone mass of one standard deviation below the mean peak bone mass in healthy young adult women  Any history of cancer except the following: (a) superficial basal or squamous cell carcinoma of the skin which has been completely resected or resolved by a topical chemotherapeutic agent, and (b) other malignancies treated curatively at least 10 years previously, without any evidence of recurrence Abnormal transvaginal ultrasound that has not been investigated and cleared by endometrial biopsy History of low-trauma hip or spine fracture previously diagnosed Serious residuals from cerebral vascular disease Diabetes mellitus, except for easily controlled, non-insulin dependent or insulin dependent diabetes mellitus without significant microvascular or neuropathic disease Serum creatinine >1.9 mg/dl Chronic liver disease or alcoholism Treatment with bone active agents such as fluoride or bisphosphonates within the previous 2 years Treatment with calcitonin, estrogen, or a selective estrogen receptor modulator within the previous 6 months Systemic corticosteroid therapy at pharmacologic levels for more than 6 months duration
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Osteoporosis Chronological age: 6.0 0 years. Study population will be restricted to children greater than 12 years of age until 8 patients have completed 6 months of the study or safety data is available from a comparable study AP Lumbar spine bone mineral density less than or equal to -2 standard deviations for age matched controls (z-score) using Hologic QDR machine Normative data published by Faulkner will be used to calculate Z-scores Patients with Idiopathic Juvenile Osteoporosis, osteoporosis (BMD less than -2 SD compared to age-matched controls) in a child with no identifiable etiology. Children with IJO and delayed puberty will have their z-score calculated on the basis of bone age  Inability to swallow pills or comply with administration instructions Upper gastrointestinal tract disease Creatinine clearance greater than or equal to 35 mL per min per 1.73 square meters Prior treatment with bisphosphonates Concurrent therapy with oral aspirin or salicylate containing compounds, excluding delayed-release salicylates which act in the distal gastrointestinal tract (for example, mesalamine, sulfasalazine, etc...) Hypocalcemia Treatment with hGH or calcitonin in the preceding 6 months Inability to undergo dual energy x-ray absorptiometry Positive pregnancy test In females, sexual activity without an effective method of contraception
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 18.0-32.0,  Healthy Osteoporosis Premature Ovarian Failure Patients with karyotypically normal spontaneous premature ovarian failure (as defined by screening protocol 91-CH-0127, i.e. women who have at least 4 months of amenorrhea, two FSH levels above 40 mIU/ml, at least one month apart, and a normal 46, XX karotype, diagnosed with premature ovarian failure prior to the age of 40) who are between the age of 18 and 42 years will be candidates  General Smokers (more than 2 cigarettes per day) Alcohol users (more than 2 drinks of alcohol per day) Body mass index (BMI, kg/m(2)) greater than or equal to 30 and less than or equal to 19 Previous history of hip fracture or other active hip pathology Abnormalities of the hip precluding the assessment of bone mineral density Major dermatologic disorders, or a history of skin sensitivity to adhesive bandages, tape or transdermal matrix patches Hirsutism score greater than 8 Acne score greater than 1 Hysterectomy
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-72.0,  Osteoporosis Postmenopausal Weight within 90% to 120% of ideal body weight or more months since last menstrual period New York Metro Area resident  History of cancer, diabetes, or heart disease Smoker
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 45.0-70.0,  Postmenopause Hot Flashes Osteoporosis, Postmenopausal Resident of the New York Metro Area Postmenopausal Weight within 90% to 120% of ideal body weight
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis Veterans aged 50 and older drawn from two existing VA cohorts, the Normative Aging Study (NAS) and the Veterans Health Study (VHS)
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-75.0,  Osteoporosis Healthy caucasian postmenopausal females between 50-75 years of age with low bone mineral density at the lumbar spine or hip as measured using dual energy x-ray absorptiometry or DXA ON estrogen replacement treatment for at least three years  Heart, vascular, kidney, liver, lung, hormonal, musculo-skeletal disease (other than osteoporosis), rheumatic, blood diseases are High blood pressure Pregnancy Cancer Alcohol or drug dependence Prior use of a drug treatment for osteoporosis such as PTH, bisphosphonates, raloxifene, or calcitonin within the preceding five years
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Osteoporosis Osteoporosis, Postmenopausal For Patients PACE beneficiaries who filled at least one prescription for a drug of any type in the year prior to the study At high risk for osteoporosis: women and men 75 years or older, patients taking glucocorticoids or psychoactive medications, patients diagnosed with rheumatoid arthritis, and patients with a past fracture Have had an outpatient visit with a participating doctor based on Medicare outpatient claims For Physicians Primary prescribing physicians for PACE beneficiaries
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Postmenopausal Osteoporosis -postmenopausal for at least 3 years, with osteoporosis at any of the following sites: [BMD > 2.0 standard deviations below young normal mean bone mass for the hip trochanter, PA lumbar spine (L1 to L4), total hip, or femoral neck based on the normative database provided by each individual manufacturer] willing to take study-supplied calcium and vitamin D supplement (or equivalent) and to discontinue any non-study calcium supplements for run-in period and the duration of the study  -pregnant or lactating, or of childbearing potential participated in another therapeutic trial with an investigational compound within 30 days of randomization history of hypersensitivity to any component of ibandronate tablets or has hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption an abnormality of the esophagus which delays esophageal emptying such as stricture or achalasia unable to stand or sit upright for at least 60 minutes once a month current use of illicit drugs, or history of drug or alcohol abuse within the past five years has any of the following: hypocalcemia; any severe malabsorption syndrome; moderate or severe hypertension which is uncontrolled; new onset angina or myocardial infarction within six months of entry into the study; evidence for impaired renal function; organ transplantation; or other significant end organ diseases (genitourinary, cardiovascular, endocrine, hepatic, psychiatric, renal, hematologic, or pulmonary) history of or evidence of metabolic bone disease (other than postmenopausal bone loss) clinical fracture in the past year is receiving or has received treatment prior to randomization which might influence bone turnover
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-64.0,  Osteoporosis Members of the Harvard Pilgrim Health Plan  Individuals who are not members of the Harvard Pilgrim Health Plan
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Opiate Dependence Osteoporosis Erectile Dysfunction Hypogonadism age 18 to 50 methadone maintenance for at least 12 months (for cases) stable dose of methadone for 6 months (for cases) willing to participate in the study competency in English male  previous diagnosis of sexual dysfunction previous diagnosis of osteoporosis serum creatinine > 2 mg/dL chronic opiate use (for controls) congestive heart failure illicit drug use
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis fracture caused by osteoporosis fifty years or more of age informed consent  Physically or mental state that does not participation
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Osteoporosis Osteopenia Postmenopausal women with low trauma distal radius fracture (confirmed by x-ray) Can be taking Didrocal (etidronate), Miacalcin (calcitonin),or hormone replacement therapy   Women with fractures of the elbow, mid radius, scaphoid, or injury to wrists (without actual fracture) Significant cognitive impairment (which would preclude them from filling out simple questionnaires) Women already taking osteoporosis therapy, ie. either Fosamax (alendronate), Actonel (risedronate), or the selective estrogen receptor modulator, Evista (raloxifene)
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 25.0-44.0,  Osteoporosis women aged between 25 and 44 years of age  previous had measurement of bone densitometry thyroid disease renal failure malignancy rheumatoid arthritis history of hysterectomy hormone replacement therapy were pregnant or planning pregnancy within 2 years of study entry lactating
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Hip Fractures Osteoporosis Any North Carolina long-term care facility with ten residents who had had a hip fracture or osteoporosis diagnosis
Patient description: A 51-year-old woman is seen in clinic for advice on osteoporosis. She has a past medical history of significant hypertension and diet-controlled diabetes mellitus. She currently smokes 1 pack of cigarettes per day. She was documented by previous LH and FSH levels to be in menopause within the last year. She is concerned about breaking her hip as she gets older and is seeking advice on osteoporosis prevention.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Osteoporosis Healthy as assessed by the health and lifestyle questionnaire physical examination results of the pre-study laboratory tests Caucasian women Postmenopausal (≥12 ≤60 months since last menses), determined by interview FSH level ≥ 20 IU/l Body Mass Index (BMI) ≥22  Participation in any clinical trial including blood sampling and/or administration of products up to 90 days before Day 01 of this study Participation in any non-invasive clinical trial up to 30 days before Day 01 of this study, including no blood sampling and/or oral, intravenous, inhalatory administration of products Osteoporosis, determined by Questionnaire (spontaneous bone fractures, use of medication to treat osteoporosis) DXA scans of the lumbar spine between day -14 and day 1 of the study; threshold is set at -2z score of BMD Severe scoliosis (curvature of the spine) that could interfere with the ability of the subject to go through the DXA scanning procedure and/or with a correct reading of the DXA scans Having a history of medical or surgical events that may significantly affect the study outcome, including surgical menopause (including hysterectomy) antecedents and high familiar incidence of breast and/or endometrial cancer gastrointestinal disease (Crohn's, short bowel syndrome, coeliac disease, gastroenteritis episodes the month before the start of the study)